J9271Inj pembrolizumab
Published CMS Medicare Part B payment-limit context for J9271, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$60.645
per 1 MG · Medicare Part B
Down 1.0%from $61.251 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$61.7617$57.0923
2024-Q4: $58.216; 2025-Q1: $57.603; 2025-Q2: $59.349; 2025-Q3: $58.562; 2025-Q4: $60.291; 2026-Q1: $59.726; 2026-Q2: $61.251; 2026-Q3: $60.645
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Pembrolizumab ingredient family (FDA data as of August 20, 2026).
Keytruda
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Presentation updates
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.